Physician Labeling Rule Will Get Four "Companion" Guidances From FDA
This article was originally published in The Pink Sheet Daily
Executive Summary
Guidances will discuss labeling format, adverse reactions, clinical studies and warnings, FDA's Behrman says. Structured product labeling will roll out this fall and should be fully populated by October 2006, she says.
You may also be interested in...
Drug Labeling Rule Returns To OMB
FDA's physician labeling rule has been resubmitted to the White House Office of Management & Budget
NME Slowdown Shows Market Pressure On Me-Toos, Not FDA Caution – Lutter
DURHAM, N.C. - The decline in FDA's tally of new molecular entity approvals stems from fewer approvals of non-innovative products in recent years, while approvals of truly innovative products has largely held steady, according to FDA Deputy Commissioner for Policy, Planning and Preparedness Randall Lutter
Amgen Aranesp, Vectibix Setbacks Illustrate Risks Of Real World Trials
Amgen's failed Anemia of Cancer trial of Aranesp and Panitumumab Advanced Colorectal Cancer Evaluation (PACCE) trial of Vectibix may illustrate the potential pitfalls facing sponsors that conduct "real world" trials of their products